TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02971423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulbactam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulbactam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulbactam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem/Cilastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem/Cilastatin
Study: NCT00768989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: Capsules, Oral, 300 mg, twice daily, 96 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Tablet, Oral, 400 mg, twice daily, 96 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir
Description: Capsules, Oral, 300 mg, once daily, 96 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Description: Capsules, Oral, 100 mg, once daily, 96 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir/Emtricitabine
Description: Tablet, Oral, 300-mg Tenofovir/200-mg Emtricitabine, once daily, 96 weeks
Study: NCT00285896

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon-like-peptide-1 (7-36) amide
Description: Continuous, subcutaneous GLP-1 at a dose of 4.8 pmol/kg/min for 51 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: continuous subcutaneous placebo infusion at a dose of 4.8 pmol/kg/min for 51 hours
Study: NCT00888693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-288
Description: See Arm Description for details.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-288
Description: See Arm Description for details.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-288
Description: See Arm Description for details.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-288
Description: See Arm Description for details.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-288
Description: See Arm Description for details.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-288
Description: See Arm Description for details.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-288
Description: See Arm Description for details.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-288
Description: See Arm Description for details.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-288
Description: See Arm Description for details.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: See Arm Description for details.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: See Arm Description for details.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: See Arm Description for details.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: See Arm Description for details.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: See Arm Description for details.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: See Arm Description for details.
Study: NCT02996331

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4 hour repositioning
Description: It is expected that repositioning frequency can be extended for NH residents who are low, moderate, and high risk for pressure ulcer (PrU) development and on visco-elastic (VE) high-density foam support-surfaces without compromising PrU incidence. This intervention will include a 4 hour repositioning interval.
Study: NCT02414932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine hydrochloride 0.5 mg/kg; Pfizer Healthcare Ireland

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam 0.045 mg/kg; Roche Products Ireland Ltd
Study: NCT00888693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: See Arm Description for details.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: See Arm Description for details.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: See Arm Description for details.
Study: NCT02904798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polypodium Leucotomos
Description: - PL 240mg to be taken by the patient for 28 days prior to irradiation with visible light
Study: NCT05638932

Intervention type: DRUG
Intervention: Initiation of IL6Ri (tocilizumab or sarilumab) versus JAKi (baricitinib or tofacitinib) added to systemic corticosteroids of interest (CSI)
Description: Real world use of either IL6Ri (TCZ or SAR) or JAKi (BAR or TOF)
Study: NCT02745197

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Supplement
Description: Participants will take 2 capsules, containing the nutritional supplement, 3 times per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take 2 capsules, containing a placebo, 3 times per day.
Study: NCT02834481

Intervention type: DEVICE
Group type: OTHER
Intervention: ANI/NIPE
Description: ANI/NIPE monitors is a continuous noninvasive measurement of the parasympathetic tone, as a component of the autonomous nervous system. It uses the tiny variations of heart rate induced by each respiratory cycle (natural or induced) to quantify parasympathetic tone (respiratory sinus arrhythmia).
Study: NCT02050113

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom Made Fenestrated or Branched Stent Graft
Description: The surgeon will place a custom made graft, t-Branch device or modify commercially available stent grafts to match the anatomy of the patient being treated. Small fenestrations (holes) will be made in the stent graft so that additional stents can be inserted through the fenestration and into the blood vessels that lead to the kidneys, intestines or liver. These stents allow blood to flow freely to these organs. If the aneurysm is in the aortic arch stents may be placed in the carotid and subclavian arteries. This surgery is done through small incisions in the groin and sometimes in the upper arm.
Study: NCT03205124

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation
Description: The experimental treatment involves implantation of 2 sterilized fine-gauge Teflon coated wires percutaneously. The ends of the wire are stripped for conductivity. Electrical stimulation is given at a fixed continuous frequency of 20Hz. The stimulus intensity is the maximum tolerable limit. The wires are then taped to the skin with surgical wound tape at a location away from the wound for strain relief. To ensure sterility, care is taken to dress the sutured wound and hand, as well apply the splint.~The wires are removed either immediately at the conclusion of the pre-operative appointment and immediately after surgery or at the first surgical follow-up with dressing change, within one week of surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation
Description: The experimental treatment involves implantation of 2 sterilized fine-gauge Teflon coated wires percutaneously. The ends of the wire are stripped for conductivity. Electrical stimulation is given at a fixed continuous frequency of 20Hz. The stimulus intensity is the maximum tolerable limit. The wires are then taped to the skin with surgical wound tape at a location away from the wound for strain relief. To ensure sterility, care is taken to dress the sutured wound and hand, as well apply the splint.~The wires are removed either immediately at the conclusion of the pre-operative appointment and immediately after surgery or at the first surgical follow-up with dressing change, within one week of surgery.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: The experimental treatment involves implantation of 2 sterilized fine-gauge Teflon coated wires percutaneously. The ends of the wire are stripped for conductivity. Electrical stimulation is begun until the patient senses the stimulation, then the stimulation is discontinued.The wires are then taped to the skin with surgical wound tape at a location away from the wound for strain relief. To ensure sterility, care is taken to dress the sutured wound and hand, as well apply the splint.~The wires are removed either immediately at the conclusion of the pre-operative appointment and immediately after surgery or at the first surgical follow-up with dressing change, within one week of surgery.
Study: NCT04467073

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online RIT
Description: Online RIT presents RIT techniques in four sequential learning modules: (1) Setting Up For Success (2) Imitating your Child (3) Describing Play (4) Teaching Object Imitation. Each learning module includes an instructional video, quiz, interactive exercises, and at-home planning and reflection. The website also includes a video library, Frequently Asked Questions, downloadable visual aids, links to relevant external resources, and a customizable dashboard that allows users to track their individualized goals and the amount of time they have spent working on their goals (e.g., practice log).
Study: NCT00602563

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AMP
Description: The AMP is a computer-delivered attention modification protocol designed to enhance attention disengagement from threatening stimuli. The AMP protocol includes twelve 20-min sessions delivered over a 6-week period. During each session, participants will see 240 trials consisting of the various combinations of probe type (E or F), probe position (top or bottom), and word type (Neutral or Threat). 192 trials include one neutral word and one threat word: 2 (probe type) X 2 (probe position) X 2 (repetitions) X 24 (word pairs). On trials where participants see one neutral word and one threat word (i.e., 80% of the trials), the probe always follows the neutral word.
Study: NCT04306614

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endobronchial Ultrasound guided Transbronchial Fine Needle Aspiration
Description: Bronchoscopic procedure to allow for sampling mediastinal lymphadenopathy or proximal lung tumours under real-time ultrasound guidance.
Study: NCT00602563

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Applied Relaxation (AR)
Description: Applied Relaxation (AR) is a behavioral, skills-based intervention where individuals learn ways to reduce the physiological cues associated with anxiety and worry (Öst, 1987; Siev \& Chambless, 2007)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Clinical Monitoring (CM)
Description: participants assigned to the clinical monitoring (CM) condition will receive the same information about the nature of GAD provided to participants in the active conditions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combining the AMP and AR
Description: The AMP is a computer-delivered attention modification protocol designed to enhance attention disengagement from threatening stimuli. The AMP protocol includes twelve 20-min sessions delivered over a 6-week period. During each session, participants will see 240 trials consisting of the various combinations of probe type (E or F), probe position (top or bottom), and word type (Neutral or Threat). 192 trials include one neutral word and one threat word: 2 (probe type) X 2 (probe position) X 2 (repetitions) X 24 (word pairs). On trials where participants see one neutral word and one threat word (i.e., 80% of the trials), the probe always follows the neutral word. Applied Relaxation (AR) is a behavioral, skills-based intervention where individuals learn ways
Study: NCT04306614

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Endobronchial Ultrasound guided Transbronchial Fine Needle Aspiration
Description: Bronchoscopic procedure to allow for sampling mediastinal lymphadenopathy or proximal lung tumours under real-time ultrasound guidance.
Study: NCT01489319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salsalate
Description: 4 out of 10 subjects will receive salsalate 2.0 gm twice a day for 12 weeks; 4 out of 10 subjects will receive PCE 200 mg containing 20% resveratrol twice a day for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salsalate
Description: 4 out of the 10 subjects will receive salsalate 2.0 gm twice a day for 12 weeks; 4 out of 10 subjects will receive PCE 200 mg containing 20% resveratrol twice a day for 12 weeks.
Study: NCT00956059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone, FK506, MMF
Description: 1.in the initial 3 months，prednisone dosage is 30mg per day；in the following 4\~6 months，prednisone dose decreased to 20mg per day，then tapered gradually to 10mg per day；2.the initial dosage of FK506 is 0.2mg/kg/d, twice per day，the maintenance dosage is adjust to the serum concentration of FK506 (is maintained at the level of 6\~10μg/L)；3. the initial dosage of MMF is 1.0g, twice per day，then reduce to 0.75 g, twice per day after 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: In the initial 16\~24 weeks，prednisone is given at full dose of 1mg/kg/d，then prednisone is tapered gradually，the whole course of treatment is 52 weeks
Study: NCT02246049

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Given IV
Study: NCT02891408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Firsocostat
Description: Capsule(s) administered orally on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Firsocostat
Description: Capsule(s) administered orally on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Firsocostat
Description: Capsule(s) administered orally on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Firsocostat
Description: Capsule(s) administered orally on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Firsocostat
Description: Capsule(s) administered orally on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Firsocostat
Description: Capsule(s) administered orally on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Tablet administered orally on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Tablet administered orally on Day 1
Study: NCT02246049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study: NCT01865422

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: parent-proxy QoL chronic cough specific questionnaire (PC-QOL)
Study: NCT00558246

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermabond Protape (Prineo)
Description: cyanoacrylate and pressure sensitive adhesive mesh - topical skin adhesive

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suture
Description: Topical Suturing
Study: NCT01572181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine IV- Busulfan IV (Busilvex®) - Anti-thymocyte globulines (Thymoglobuline®)
Description: * IV fludarabine (30 mg/m²/day for 5 days)~* IV Busulfan (Busilvex 3.2 mg/kg/day for 4 days) (the Busulfan dose is to be adapted to the weight of the child according to the drug label)~* Anti-thymocyte globulines (Thymogolubuline, 2.5 mg/kg/day for 2 days).
Study: NCT00701454

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT02322281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rociletinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rociletinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed or gemcitabine or paclitaxel or docetaxel
Study: NCT02478710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aerosolized Tobramycin or Vancomycin
Description: Tobramycin: 300 mg diluted in 5 mL of 0.9% normal saline q.12h. Vancomycin: 125 mg diluted in 5 mL 0.9% normal saline q.8h.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aerosolized Placebo
Description: Placebo tobramycin: 5 ml 0.9% normal saline q. 12h. Placebo vancomycin: 5m 0.9% normal saline q. 8 hr.
Study: NCT03474614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: The medication will be administered so that patient receives a minimum of 7- days and maximum of 10-days of treatment with propranolol prior to planned surgical resection of CCM (routine care)

Intervention type: GENETIC
Group type: OTHER
Intervention: DNA and RNA Analysis
Description: During the operative procedure, a small sample of the patient's blood will be obtained and small (1 to 2cc) tissue sample from the resected cavernous malformation will be collected. The blood and tissue samples will be labeled and stored for subsequent DNA and RNA analysis

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA and RNA Analysis
Description: During the operative procedure, a small sample of the patient's blood will be obtained and small (1 to 2cc) tissue sample from the resected cavernous malformation will be collected. The blood and tissue samples will be labeled and stored for subsequent DNA and RNA analysis
Study: NCT02785848

Intervention type: OTHER
Intervention: Interviews and Surveys
Description: The investigators will perform semi-structured interviews and surveys on this cohort
Study: NCT05459467

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 12 weeks high intensity exercise programme
Study: NCT06227871

Intervention type: PROCEDURE
Intervention: Exploratory laparotomy
Description: Exploratory laparotomy with interventions addressing pancreatic injuries Grade 1-5 including pancreatic interventions including subtotal pancreatectomy, distal pancreatectomy, pancreatic ligation, pyloric diversion, or simple drainage of the pancreas.

Intervention type: PROCEDURE
Intervention: Exploratory laparotomy
Description: Exploratory laparotomy with interventions addressing pancreatic injuries Grade 1-5 including pancreatic interventions including subtotal pancreatectomy, distal pancreatectomy, pancreatic ligation, pyloric diversion, or simple drainage of the pancreas.
Study: NCT04516720

Intervention type: OTHER
Intervention: data collection
Description: Diagnostic data : date and description of first symptoms,date of radiological diagnosis, tumor localization, number of lesions, date of histological diagnosis, histological diagnostic mode, histological diagnosis, WHO grade (I, II, III or IV), immunohistochemic data, molecular alterations therapeutic sequence : type of treatment, baseline exam before each treatment, surgery, radiothérapy, systemic treatment, clinical study, follow up until death
Study: NCT00447720

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PATH
Description: We have chosen to translate two proven prevention programs for delivery to the SMI populations by their case managers. These interventions are the Brief Counseling intervention from the Project Respect program and the Community-Based Outreach Program (CBOM). Together we will translate them into ongoing case management for SMI persons who also abuse substances in the Preventing AIDS through Health Project (PATH). Consistent with other findings regarding HIV infections among the SMI, in our preliminary studies we found that these individuals are at much higher risk within the population of persons being served in Philadelphia.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PATH
Description: We have chosen to translate two proven prevention programs for delivery to the SMI populations by their case managers. These interventions are the Brief Counseling intervention from the Project Respect program and the Community-Based Outreach Program (CBOM). Together we will translate them into ongoing case management for SMI persons who also abuse substances in the Preventing AIDS through Health Project (PATH). Consistent with other findings regarding HIV infections among the SMI, in our preliminary studies we found that these individuals are at much higher risk within the population of persons being served in Philadelphia.
Study: NCT01500772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisporivir
Description: ALV 200 mg soft gel capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: PEG 180 μg administered via subcutaneous (s.c.) injection once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
Study: NCT04453865

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project EMPOWER
Description: Project EMPOWER is a web-based, self-administered SSI for parents that takes about 30 minutes to complete

Intervention type: OTHER
Group type: OTHER
Intervention: Online Resources and Referrals
Description: Information sheet containing materials about the nature of child anxiety and a list of national resources related anxiety treatment.
Study: NCT02531217

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATYR1940
Description: Concentrate for solution for infusion
Study: NCT01227798

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon alfacon-1
Description: 15 mcg at fill volume of 0.5mL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline
Study: NCT03282461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABY-029
Description: A sample size of 6-12 patients in this open label, single center, clinical trial of ABY-029. Administration will occur as a single intravenous injection to subjects with operable head and neck cancer approximately 1-3 hours prior to surgery.
Study: NCT00537602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: miglustat

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02926872

Intervention type: OTHER
Intervention: There is no intervention in the study
Study: NCT01360671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Loading dose of 0.1 mg/kg for 30 minutes followed by maintenance treatment of 0.03 mg/kg.h for up to 14 days
Study: NCT04365972

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM)
Description: A home-delivered version of ABM will be administered in this open trial. ABM will be comprised of 5 sessions with a variation of the dot-probe task in which the target probe always replaces the neutral stimuli to induce diversion of attention away from threat. This condition was found effective in reducing anxiety symptoms.